Alka-Seltzer Plus needs more time to re-label
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare asks FDA for more time to change packaging for its cold and flu relief line to comply with a final rule for labeling acetaminophen products. Thirteen stock-keeping units under the Alka-Seltzer Plus brand will be unable to accommodate organ-specific warnings by the rule's effective date of April 29, Bayer says in a Feb. 16 1letter to the agency. The firm's VP of Regulatory Affairs Leonard Baum explains, "Bayer was forced to wait" for FDA's technical amendment of Nov. 25, 2009, which clarified that smaller immediate containers such as blister cards and sachets must bear liver injury and stomach bleeding warnings (2"The Tan Sheet" Nov. 30, 2009). Bayer asks for a 12-month deferral to re-label ASP foil pouches and stick packs, and a six-month deferral to re-label the companion cartons. A spokeswoman said the company has not yet heard from FDA
You may also be interested in...
FDA Requires Liver Injury Warning On Acetaminophen Stick Packs, Sachets
Acetaminophen products sold in stick packs and sachets must carry warnings about the risk of liver injury by April 29, 2010, a technical amendment to the final rule for internal analgesics says
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.